An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History… (NCT03338764) | Clinical Trial Compass
WithdrawnPhase 3
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
Stopped: no participants enrolled
0Started 2023-05
Plain-language summary
The purpose of this study is to assess the efficacy and pattern of use of the combination drug product SM-1 in adults who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or placebo to take at home as needed over the course of 3 months treatment period.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Experienced at least 1 prior episode of transient insomnia meeting all of the following criteria: difficulty falling asleep or staying asleep; next day impairment or distress associated with the disturbed sleep; frequency of 1 to 7 nights per week; duration of less than 1 month or more than 1 month of intermittent episodes.
* Routinely spends 6.5 - 9.5 hours in bed each night, with bed time varying no more than 2 hours over a week.
* Body Mass Index (BMI) between 19 and 32 kg/m2.
* Good general health, as determined by a thorough medical, sleep and psychiatric history review, brief physical examination including vital sign measurements, and an assessment of screening laboratory test results.
* Agrees, for the duration of the study, to take only study drug to address difficulty falling asleep or staying asleep, and to not drink alcohol within 2 hours of expected bedtime.
Exclusion Criteria:
* Females who are pregnant, breast-feeding, or planning a pregnancy during the study period.
* Clinically significant medical disorder or currently unstable medical condition that, in the opinion of the investigator, would confound the results of the study.
* Abnormal laboratory value at screening, judged clinically significant by the investigator.
* History or current evidence of severe hepatic (liver) impairment.
* Clinically significant psychiatric illness, or the history or presence of a major psychiatric illness in the past year.
* Has a significant risk (in th…